JP2002541255A - Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物 - Google Patents

Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物

Info

Publication number
JP2002541255A
JP2002541255A JP2000610851A JP2000610851A JP2002541255A JP 2002541255 A JP2002541255 A JP 2002541255A JP 2000610851 A JP2000610851 A JP 2000610851A JP 2000610851 A JP2000610851 A JP 2000610851A JP 2002541255 A JP2002541255 A JP 2002541255A
Authority
JP
Japan
Prior art keywords
geldanamycin
chemical compound
hsp
compound according
linker
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000610851A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002541255A5 (https=
Inventor
ローゼン、ニール
クダック、スコット、ディー
ダニシェフスキイ、サミュエル、ジェイ
ゼーン、ファーツォン、エフ
− ロレンツィーノ、ローラ セップ
アウェアフェッリ、アウワセック
Original Assignee
スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スローン − ケッタリング インスティチュート フォー キャンサー リサーチ filed Critical スローン − ケッタリング インスティチュート フォー キャンサー リサーチ
Publication of JP2002541255A publication Critical patent/JP2002541255A/ja
Publication of JP2002541255A5 publication Critical patent/JP2002541255A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D225/00—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom
    • C07D225/04—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D225/06—Heterocyclic compounds containing rings of more than seven members having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2000610851A 1999-04-09 2000-04-07 Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物 Pending JP2002541255A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12859399P 1999-04-09 1999-04-09
US60/128,593 1999-04-09
PCT/US2000/009512 WO2000061578A1 (en) 1999-04-09 2000-04-07 Methods and compositions for degradation and/or inhibition of her-family tyrosine kinases

Publications (2)

Publication Number Publication Date
JP2002541255A true JP2002541255A (ja) 2002-12-03
JP2002541255A5 JP2002541255A5 (https=) 2007-07-05

Family

ID=22436066

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000610851A Pending JP2002541255A (ja) 1999-04-09 2000-04-07 Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物

Country Status (6)

Country Link
US (1) US7271160B2 (https=)
EP (1) EP1169319A4 (https=)
JP (1) JP2002541255A (https=)
AU (1) AU769235B2 (https=)
CA (1) CA2370007A1 (https=)
WO (1) WO2000061578A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU4093799A (en) 1998-05-22 1999-12-13 Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and therapies based thereon
US7220552B1 (en) 1999-11-19 2007-05-22 The Board Of Trustees Of The Leland Stanford Junior University Bifunctional molecules and their use in the disruption of protein-protein interactions
WO2001035978A1 (en) 1999-11-19 2001-05-25 The Board Of Trustees Of The Leland Stanford Junior University Targeted bifunctional molecules and therapies based thereon
US6887842B1 (en) * 1999-11-19 2005-05-03 The Board Of Trustees Of The Leland Stanford Junior University Modulating a pharmacokinetic property of a drug by administering a bifunctional molecule containing the drug
US20020002169A1 (en) 1999-12-08 2002-01-03 Griffin John H. Protein kinase inhibitors
ATE526019T1 (de) 2000-07-28 2011-10-15 Sloan Kettering Inst Cancer Verfahren zur behandlung von zellproliferationen störungen und virusinfektionen
DE60120427D1 (de) 2000-08-25 2006-07-20 Sloan Kettering Inst Cancer Radicicol und monocillin und ihre analogen und ihre anwendungen
US7439359B2 (en) 2000-11-02 2008-10-21 Sloan-Kettering Institute For Cancer Research Small molecule compositions for binding to hsp90
WO2002094196A2 (en) 2001-05-23 2002-11-28 Sloan Kettering Institute For Cancer Research Method of treatment for cancers associated with elevated
US6872715B2 (en) * 2001-08-06 2005-03-29 Kosan Biosciences, Inc. Benzoquinone ansamycins
CA2460498A1 (en) 2001-09-24 2003-04-03 Conforma Therapeutics Corporation Process for preparing 17-allyl amino geldanamycin (17-aag) and other ansamycins
EP1923061A1 (en) 2001-09-24 2008-05-21 Conforma Therapeutic Corporation Process for preparing 17-Allyl amino geldanamycin (17-AAG) and other ansamycins
GB0202871D0 (en) * 2002-02-07 2002-03-27 Cancer Res Ventures Ltd Assays,methods and means
US7259156B2 (en) 2004-05-20 2007-08-21 Kosan Biosciences Incorporated Geldanamycin compounds and method of use
CA2572318A1 (en) * 2004-07-02 2006-01-12 Neutec Pharma Plc Treatment of cancer
US20060105941A1 (en) * 2004-11-12 2006-05-18 Allergan, Inc. Mixed antibiotic codrugs
AU2006230447A1 (en) 2005-03-30 2006-10-05 Conforma Therapeutics Corporation Alkynyl pyrrolopyrimidines and related analogs as HSP90-inhibitors
WO2008005937A2 (en) 2006-06-30 2008-01-10 Sloan-Kettering Institute For Cancer Research Treatment of neurodegenerative diseases through inhibiton of hsp90
US20100113355A1 (en) 2007-04-27 2010-05-06 Naresh Chennamsetty Novel antibody molecules and nucleic acids binding to fungal stress protein hsp90
WO2010028389A1 (en) * 2008-09-08 2010-03-11 The Methodist Hospital Research Institute Image-guided energy deposition for targeted drug delivery
JP5941407B2 (ja) 2009-10-07 2016-06-29 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害剤
CN103596955B (zh) 2011-04-05 2016-11-16 索隆-基特林癌症研究协会 Hsp90抑制剂
JP6266506B2 (ja) 2011-04-05 2018-01-24 スローン − ケッタリング インスティチュート フォー キャンサー リサーチ Ｈｓｐ９０阻害物質
US9446175B2 (en) 2011-06-03 2016-09-20 Yale University Compositions and methods for treating and preventing neointimal stenosis
US20140079636A1 (en) 2012-04-16 2014-03-20 Dinesh U. Chimmanamada Targeted therapeutics
EP3738594A1 (en) 2013-09-10 2020-11-18 Madrigal Pharmaceuticals, Inc. Targeted therapeutics having an hsp90 ligand as binding moiety
WO2015066053A2 (en) 2013-10-28 2015-05-07 Synta Pharmaceuticals Corp. Targeted therapeutics
EP3099332A4 (en) 2014-01-29 2017-06-21 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
JP6576942B6 (ja) 2014-03-03 2019-11-27 マドリガル ファーマシューティカルズ インコーポレイテッド 標的治療薬
MA39483A (fr) 2014-03-18 2015-09-24 Synta Pharmaceuticals Corp Agents thérapeutiques cibles
KR20200016874A (ko) 2017-06-20 2020-02-17 마드리갈 파마슈티칼스 인코포레이티드 표적화 치료제를 포함하는 병용 요법
CA3067572A1 (en) 2017-06-20 2018-12-27 Madrigal Pharmaceuticals, Inc. Targeted therapeutics
CN117700313B (zh) * 2023-12-14 2025-02-14 怒江绿色香料产业研究院 一种羟基十四烯醛及其制备方法和应用

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPH05148205A (ja) * 1990-10-11 1993-06-15 Merck & Co Inc 対称構造を有するｈｉｖプロテアーゼ阻害剤
JPH08506356A (ja) * 1993-06-29 1996-07-09 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
WO1998051702A1 (en) * 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261989A (en) * 1979-02-19 1981-04-14 Kaken Chemical Co. Ltd. Geldanamycin derivatives and antitumor drug
US5650430A (en) 1990-06-06 1997-07-22 Sankyo Company, Limited Radicicol derivatives, their preparation and their anti-tumor activity
US5932566A (en) * 1994-06-16 1999-08-03 Pfizer Inc. Ansamycin derivatives as antioncogene and anticancer agents
KR19990076764A (ko) 1996-10-25 1999-10-15 히라타 다다시 래디시콜 유도체
US5968921A (en) * 1997-10-24 1999-10-19 Orgegon Health Sciences University Compositions and methods for promoting nerve regeneration

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS55111469A (en) * 1979-02-19 1980-08-28 Kaken Pharmaceut Co Ltd Novel geldanamycin derivative, its preparation, and antitumor drug comprising it as active ingredient
JPH05148205A (ja) * 1990-10-11 1993-06-15 Merck & Co Inc 対称構造を有するｈｉｖプロテアーゼ阻害剤
JPH08506356A (ja) * 1993-06-29 1996-07-09 ファイザー・インク． 抗癌遺伝子剤および抗癌剤としてのアンサマイシン誘導体
WO1998051702A1 (en) * 1997-05-14 1998-11-19 Sloan-Kettering Institute For Cancer Research Methods and compositions for destruction of selected proteins

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
JPN6010057431, Ｃａｎｃｅｒ Ｃｈｅｍｏｔｈｅｒ． Ｐｈａｒｍａｃｏｌ．, 1998, ４２, ２７３−２７９ *
JPN6010057433, Ｊ．Ｍｅｄ．Ｃｈｅｍ．, 1995, ３８, ３８１３−３８２０ *
JPN6010057435, Ｃｅｌｌ, 1997, ９０, ６５−７５ *
JPN6010057437, Ｃｅｌｌ, 1997, ８９, ２３９−２５０ *

Also Published As

Publication number Publication date
AU4223500A (en) 2000-11-14
CA2370007A1 (en) 2000-10-19
EP1169319A1 (en) 2002-01-09
AU769235B2 (en) 2004-01-22
EP1169319A4 (en) 2005-02-09
US7271160B2 (en) 2007-09-18
US20020045570A1 (en) 2002-04-18
WO2000061578A1 (en) 2000-10-19

Similar Documents

Publication Publication Date Title
JP2002541255A (ja) Ｈｅｒ族チロシンキナーゼの分解および／または阻害方法および組成物
CN109843335B (zh) 吡咯并苯并二氮杂卓缀合物
US6391913B1 (en) Derivatives of paclitaxel, method for producing same and uses thereof
Zheng et al. Identification of a geldanamycin dimer that induces the selective degradation of HER-family tyrosine kinases
EP3100731A1 (en) Ligand-cytotoxicity drug conjugate, preparation method therefor, and uses thereof
Tang et al. Bisphosphonates suppress insulin‐like growth factor 1‐induced angiogenesis via the HIF‐1α/VEGF signaling pathways in human breast cancer cells
JP2022515250A (ja) 改善された細胞標的化結合分子
EP3381474A1 (en) Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
Li et al. Development of a novel EGFR-targeting antibody-drug conjugate for pancreatic cancer therapy
JP2018507844A (ja) 抗体薬物コンジュゲート
JPH03161490A (ja) メイタンシノイドを含む細胞障害剤及び該細胞障害剤を有効成分とする医薬
HU208161B (en) Process for producing cytotoxic active ingredient - antibody conjugates and pharmaceutical compositions
TW202327661A (zh) 抗her3抗體藥物偶聯物及其組合物和用途
US20100029758A1 (en) Derivatives of isoflavones
JP2003504413A (ja) 抗腫瘍物質を含む組み合わせ調製物
Milazzo et al. ErbB2 targeted epigenetic modulation: anti-tumor efficacy of the ADC trastuzumab-HDACi ST8176AA1
US20240398823A1 (en) Dual inhibitor of histone deacetylase 6 and heat shock protein 90
JP2020508355A (ja) 腫瘍成長を阻害し且つ腫瘍に対する免疫反応を増強するための方法及び組成物
CN116036303B (zh) 一种抗体-药物偶联物及其制备方法和应用
US20060052312A1 (en) Paclitaxel hybrid derivatives
US7238682B1 (en) Methods and compositions for degradation and/or inhibition of HER-family tyrosine kinases
US12186320B2 (en) Therapeutic agent containing pyrazolo[3,4-d]pyrimidine compound as active ingredient
US20040115209A1 (en) Compound targeted for specific cells with reduced systemic toxicity
TW202502388A (zh) 包含抗cd138抗體之抗體藥物複合體
CN112402616A (zh) 一种含环丙沙星和抗体药物偶联物的药物组合物及其应用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070403

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070403

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20070426

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20101012

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110304